595 results about "Aceglatone" patented technology

The invention relates to the technical field of dye synthesis, and particularly discloses a genetically engineered bacterium for synthesizing N-acetyl blue as well as a construction method and application of the genetically engineered bacterium. The supply capacity of precursor substances glutamic acid and glutamine of the genetically engineered bacterium is high, the fermentation process is simple, the production intensity of the precursor substances glutamine and N-acetylglutamine is improved by cutting off a consumption path, relieving negative feedback inhibition and enhancing the expression level of key genes through the genetically engineered bacterium, and finally the yield of N-acetylblue reaches 41.2 g / L.

The invention relates to the technical field of synthetic biology, metabolic engineering and cell culture. The present invention provides a cell for the production of a negatively charged, preferably sialylated, oligosaccharide wherein the cell is genetically engineered to have or express, preferably overexpress, a hydrolytic UDP-N-acetyl-D-glucosamine-2-epimerase. The invention further provides the use of said cells in culture or incubation. Also described are methods of producing negatively charged, preferably sialylated oligosaccharides using the cells, and purification of the negatively charged, preferably sialylated oligosaccharides.

The present application relates to the technical field of biocatalysis and biosynthesis, and specifically discloses a natural blue pigment and a biosynthesis method therefor. The present application uses metabolically engineered bacteria to express indigoidine synthetase and phosphopantetheinyl transferase, to catalyze glutamine and N-acetylglutamine to biosynthesize a natural blue pigment N-acetylindigoidine, and deduces its molecular structure by means of mass spectrometry, nuclear magnetic resonance and other methods. The present application achieves catalytic synthesis of N-acetylindigoidine from glutamine and N-acetylglutamine in Escherichia coli, Corynebacterium glutamicum, Saccharomyces cerevisiae and Streptomyces. Compared with indigoidine, N-acetylindigoidine has a maximum absorption wavelength of 584 nm, possesses better color brightness, and has more stable coloration that is not easily faded, with a very broad application range and industrial production application prospects.

The present application relates to the technical field of biocatalysis and biosynthesis, and specifically discloses a blue pigment and a biosynthesis method thereof. In the present application, an indigoidine synthetase and a 4′-phosphopantetheinyl transferase are expressed by a metabolically engineered strain to catalyze the biosynthesis of the blue pigment N-acetyl-indigoidine from glutamine and N-acetylglutamine, and a molecular structure of the blue pigment is inferred by mass spectrometry, nuclear magnetic resonance spectroscopy, etc. The present application achieves the catalytic synthesis of N-acetyl-indigoidine from glutamine and N-acetylglutamine in Escherichia coli (E. coli), Corynebacterium glutamicum (C. glutamicum), Saccharomyces cerevisiae (S. cerevisiae), and Streptomyces. Compared with indigoidine, N-acetyl-indigoidine has a maximum absorption wavelength of 584 nm, and a stable color having high brightness that is not easy to fade. Thus, the blue pigment shows an extensive application range and a promising industrial production prospect.

The invention discloses a composition for improving the stability of oleuropein in a solution as well as a preparation method and application of the composition. The composition comprises oleuropein and at least one stabilizer, and the stabilizer is selected from the group consisting of anisic acid, lactobionic acid, glycyrrhizic acid, 3, 3-thiodipropionic acid, N-acetyl-L-glutamine, propyl-cysteine and lauramidopropyl betaine; and the pH value of the aqueous solution of the composition is 4.0-8.0. The preparation method comprises the following steps: dissolving oleuropein in water, adding the stabilizer, and uniformly mixing. Through simple physical mixing, by utilizing the synergistic effect of the specific stabilizer and the oleuropein, the degradation and discoloration of the oleuropein in the storage process are remarkably inhibited. Experiments show that after the preferable composition is preserved for 30 days in an open manner, the retention rate of the oleuropein still reaches up to 80% or above, and is far superior to that of blank control and a traditional liposome wrapping method. The composition is simple and convenient in preparation process and low in cost, and provides reliable technical support for wide application of oleuropein in liquid products such as food, medicine and cosmetics.

The invention belongs to the technical field of synthetic biology, and particularly relates to recombinant escherichia coli for efficiently producing O-acetyl-L-homoserine as well as a construction method and application of the recombinant escherichia coli. According to the invention, CRISPR-Cas9 gene editing is combined with metabolic modification, so as to precisely integrate OAH biosynthesis key nodes: introducing and overexpressing a mutant metX gene at a genome pseudogene site to enhance the expression of homoserine acetyltransferase, knocking out byproducts such as poxB and mgsA to synthesize genes, and carrying out high-yield synthesis of OAH. Corynebacterium glutamicum thrA (anti-feedback inhibition), aspB and bacillus subtilis acsA-acuA genes (construction of an acetic acid switch) are introduced, gene expression of gltA, tpiA and the like is optimized to increase supply of precursors such as acetyl CoA and the like, and finally a stable strain without plasmids, antibiotics and inducers is obtained. The production cost is effectively reduced, and the method has the advantage of high genetic stability and shows a good application prospect in OAH industrial production.

The invention relates to the technical field of aquaculture, in particular to a leiocassis longirostris intestinal health functional additive based on spermaceti soxhlet metabolite. The Leiocassis longirostris intestinal health functional additive comprises the following functional components: chondroitin sulfate, N-acetyl-D-galactosamine, 4 ', 4', 4 ', 4', 4 ', 4', 4 ', 4', 4 ', 4', 4 ', 4'- The composition is prepared from the following raw materials: 4, 6-dihydroxyflavone, polydatin, ascorbic acid, glucoside, arabinogalactan, 3-O-beta-D-galactopyranosyl-L-arabinose, tyramine, 4A-hydroxytetrahydrobiopterin, hyaluronic acid and 3-mercapto-2-butanol. According to the technical scheme, the technical problem that an existing probiotic viable bacterium preparation is difficult to meet the intestinal health management requirement in intensive culture of the leiocassis longirostris can be solved. Compared with the prior art, the scheme is more efficient, stable and safe, healthy development of the Leiocassis longirostris breeding industry can be effectively promoted, and the method has ideal application and popularization prospects.

The invention relates to a culture medium for high-density serum-free suspension culture of BHK-21 cells and application of the culture medium. The culture medium contains inorganic salt, amino acid, vitamins, energy substances, a buffer substance, an antioxidant, sterol, polyamine, an additive and an indicator, and the antioxidant comprises dihydrolipoic acid and S-acetyl-L-glutathione. According to the invention, the culture medium for serum-free suspension culture of the BHK-21 cells, which is clear in components and remarkable in culture effect, can be provided. The added dihydrolipoic acid and S-acetyl-L-glutathione are combined as antioxidants of the culture medium, so that the survival rate of BHK-21 cells cultured in the culture medium is improved while the oxidation resistance of the serum-free suspension culture medium is improved.

The invention relates to the technical field of functional food, in particular to immune regulation type prebiotic syrup with synergy of galactomannan. The active components of the composite solid beverage are prepared from the following raw materials in percentage by weight: 20%-35% of fructo-oligosaccharide, 10%-18% of galactooligosaccharide, 8%-15% of stachyose, 3%-7% of xylooligosaccharide, 5%-12% of lactitol, 5%-10% of galactomannan, 2%-5% of yeast beta-glucan and 1%-3% of N-acetylglucosamine. The composition further comprises 4-8% of inulin and 3-6% of resistant dextrin as a matrix filling and slow-release carrier, and the sum of the weight percentages of all the active ingredients and the carrier is 100%. By remodeling intestinal microecology and inhibiting inflammation pathways, the intestinal inflammation state can be remarkably improved, expression of intestinal mucosa tight junction protein is promoted, and an innovative solution is provided for people suffering from chronic bowel diseases and immune imbalance.

The invention provides an L-arginine production strain and a construction method and application thereof, corynebacterium glutamicum AJC is modified by a metabolic engineering method to obtain the L-arginine production strain, the synthesis path of arginine is optimized, and a carbon source efficiently flows to arginine by means of promoter replacement, multi-copy and the like; by introducing an exogenous gene pyrABE949 *, the supply of a precursor substance carbamyl phosphate is enhanced; by introducing an exogenous gene pntAB, a new direction is provided for supply of coenzyme NADPH, and a large amount of reducing power is provided for synthesis of arginine; an exogenous gene fxpk is introduced, an NOG system is constructed, an acetyl coenzyme A pool is enriched, a large number of acetyl coenzyme A precursors are provided, and the engineering bacterium has the characteristics of high yield and stability and has good industrial application value in the aspect of fermentation production of L-arginine.

The invention discloses a culture medium of a lacrimal gland organ and a culture method of the lacrimal gland organ, and the culture medium of the lacrimal gland organ is composed of a basic culture medium, R-spodin3, Noggin, B27, N-acetyl-L-cysteine, trehalose, vitamin C, glutathione, an adenylate cyclase activator, A8301, PGE2 and FGF10. The culture medium for lacrimal gland organ culture, provided by the invention, is prepared from various cell factor components according to an optimized proportion, and is simple and reasonable in components and rich in nutrition; when the culture medium is used for culturing the lacrimal gland organoid, the formation and growth of the organoid can be promoted, an in-vivo complex microenvironment is further simulated, the organoid is closer to an in-vivo physiological state, an organoid model is better constructed so as to evaluate the influence of drugs on lacrimal gland functions, and a new platform is provided for drug screening; and a new way is opened up for follow-up treatment of diseases such as xerophthalmia in the future.

The disclosure provides methods for synthesis of peracetylgalactosamine-1-pentanoic acid, also called peracetylated D-galactosamine C5 linker or GalNAc C5 linker, using a vegetal source as a starting material, such as vegetal-sourced D-glucosamine or D-glucosamine hydrochloride. Also provided are methods for purifying the peracetylgalactosamine-1-pentanoic acid, or GalNAc C5 linker, thus produced so that the end product comprises fewer impurities.

The invention discloses an engineered glycosyl transferase and application thereof in efficient preparation of triterpenoid saponin. The engineered glycosyl transferase is obtained by mutating serine at the 15th site of UGT74AC1 enzyme into alanine, mutating histidine at the 47th site into aspartic acid, mutating leucine at the 48th site into valine, mutating alanine at the 180th site into serine, mutating histidine at the 180th site into aspartic acid, mutating histidine at the 180th site into aspartic acid, mutating histidine at the 180th site into aspartic acid, mutating histidine at the 180th site into aspartic acid The mutant is obtained by mutating serine at the 332 site into proline, phenylalanine at the 367 site into tryptophan and lysine at the 420 site into arginine. According to the invention, the glycosyl transferase with high catalytic activity is obtained by modifying an enzyme engineering technology, and good application of the glycosyl transferase in synthesis of triterpenoid saponin is realized. The glycosyl transferase disclosed by the invention can also be coupled with sucrose synthase, or coupled with N-acetylhexosamine kinase and N-acetylglucosamine-1-uridine phosphate transferase, and acetylglucosamine is used as a glycosyl donor, so that cascade production of triterpenoid saponin with lower cost and higher efficiency is realized.

The invention discloses a synthesis method of helicid, and relates to the technical field of compound synthesis, glucose is taken as an initial raw material, allose is obtained through a series of reactions, pentaacetyl allose is prepared from allose through acetylation reaction, tetraacetyl alloside is prepared through selective deacetylation reaction, substitution reaction and nucleophilic substitution reaction, and the helicid is synthesized through a one-step method. And finally, carrying out a deacetylation reaction on the tetraacetyl alloside to prepare helicid. Helicid has the effects of calming, sleeping, easing pain and resisting inflammation, and can be applied to preparation of medicaments with corresponding effects. The preparation method of the helicid provided by the invention is simple to operate, can be used for large-scale industrial production, and overcomes the defect of insufficient yield of naturally extracted helicid.

The invention belongs to the technical field of cosmetics, particularly discloses moisturizing nano-liposome emulsion prepared by a microjet method and a preparation method of the moisturizing nano-liposome emulsion, and aims to solve the problems of poor stability of active ingredients, low transdermal absorption efficiency, single effect and non-uniform particle size in a liposome preparation process in the existing moisturizing cosmetics. The nano-liposome emulsion is prepared from glycosylglycerol, acetylchitosamine, tremella polysaccharide, a myrothamnus flabellifolia leaf / stem extract, an artemisia annua extract, a lactobacillus fermentation product, flat nuclear wood oil, hydrogenated lecithin and phosphatidylcholine. The emulsion has excellent moisturizing, soothing and repairing effects, can be used for preparing skin care products such as water aqua, emulsion and cream, and has the advantages of high utilization rate of active ingredients and good stability.

The invention discloses an N-acetylglucosamine transferase AcetRS-K23G and an application thereof, and belongs to the technical field of functional enzymes. And the amino acid sequence of the N-acetylglucosamine transferase AcetRS-K23G is as shown in SEQ ID NO. 3. The invention further discloses an application of the N-acetylglucosamine transferase AcetRS-K23G in the preparation of the chitosan oligosaccharide. The N-acetylglucosamine transferase AcetRS-K23G disclosed by the invention is obtained by performing mutation modification on the N-acetylglucosamine transferase AcetRS, and can be used for producing the chitosan oligosaccharide with the polymerization degree of 5-7, especially the heptaose, the yield of the heptaose can reach 42.01 mg / L, and the N-acetylglucosamine transferase AcetRS-K23G is an ideal functional enzyme for industrially producing the heptaose. The product spectrum of the N-acetylglucosamine transferase is widened, and the N-acetylglucosamine transferase can be used for preparing high-polymerization-degree chitosan oligosaccharide and has a wide application prospect.

The present invention relates to antibody conjugates which are particularly suitable for targeting cells expressing PTK7, in particular tumor cells. An antibody conjugate according to the present invention has structure (1): AB-[(L6) b-{Z-L-D} x] y (1) wherein AB is an antibody capable of targeting a tumor expressing PTK7; l is a joint connecting Z to D; z is a linking group; l6 is-GlcNAc (Fuc) w-(G) j-S-(L7) w '-wherein G is a monosaccharide, j is an integer in the range of 0 to 10, S is a sugar or a sugar derivative, GlcNAc is N-acetylglucosamine, and Fuc is fucose, w is 0 or 1, w' is 0, 1 or 2, and L7 is-N (H) C (O) CH2-,-N (H) C (O) CF2-or-CH2-; d is selected from the group consisting of an anthracycline, a camptothecin, a tubulysin, an endiyne, an amanitine, a duocarmycin, a maytansinoid, an aurestatin, eribulin, a BCL-XL inhibitor, a miscanthus semiaquilaria, a KSP inhibitor, a TLR agonist, an indolo-benzodiazepine dimer or a pyrrolo-benzodiazepine dimer (PBD), and an analog or prodrug thereof; b is 0 or 1; x is 1 or 2; and y is 1, 2, 3 or 4. The invention further relates to a method for preparing said antibody conjugate of structure (1) and to the use of said antibody conjugate of structure (1).

The invention relates to a gastric acid-resistant sustained-release intestinal bacteria capsule based on bionic mucous membrane-enzymolysis response and a preparation method thereof. The gastric acid-resistant sustained-release intestinal bacteria capsule comprises a core layer, an adhesive layer, an outer-layer composite film and a protective coating from inside to outside, the core layer consists of intestinal flora and a multifunctional freeze-drying protective agent; the adhesive layer is composed of trehalose, N-acetyl glucosamine and MUC2 recombinant protein; the outer-layer composite film is composed of a base material and a functional filler; the protective coating is composed of beewax and chitosan. The anti-gastric acid sustained-release intestinal bacteria capsule based on bionic mucosa-enzymolysis response provided by the invention has excellent gastric acid resistance, and the gastric acid resistance is remarkably improved; good slow release performance is achieved, and accurate slow release of enzymatic hydrolysis response can be achieved; the colonization efficiency of the intestinal bacteria can be effectively improved; the storage stability is good. The preparation method provided by the invention has the advantages of simplified steps, short time consumption, controllable core operation time and obviously shortened whole process, and is beneficial to keeping the activity of the flora.

The invention discloses yarrowia lipolytica with high yield of beta-carotene as well as a construction method and application of the yarrowia lipolytica. According to the yarrowia lipolytica engineering bacterium, geranyl diphosphate synthase gene xdGPS, phytoene dehydrogenase gene CarB, phytoene cyclization / phytoene synthesis bifunctional enzyme mutant gene GarRPY27R, acetyl-coenzyme A synthetase mutant gene ACSL641P and pyruvate ferredoxin oxidoreductase gene nifJ are integrated and expressed on a chromosome, and the yarrowia lipolytica engineering bacterium is obtained. Meanwhile, a 3-hydroxy-3-methylglutaryl CoA reductase gene HMGR (3-hydroxy-3-methylglutaryl CoA reductase) derived from the yarrowia lipolytica strain is subjected to overexpression; the yield of the beta-carotene is increased to 13.186 g / L, and the production efficiency is 0.14 g / L / h.

The invention relates to the field of food materials, and particularly discloses a gamma-aminobutyric acid and hydrolyzed egg yolk powder composite beverage capable of promoting sleep and inhibiting bone age and a preparation method of the gamma-aminobutyric acid and hydrolyzed egg yolk powder composite beverage. A gamma-aminobutyric acid and hydrolyzed egg yolk powder composite beverage capable of promoting sleep and inhibiting bone age comprises the following raw materials in percentage: 3-5% of xylitol, 3-5% of fructo-oligosaccharide, 2-4% of gamma-aminobutyric acid, 3-9% of antioxidant composite concentrated juice, 0.16-1% of purple carrot juice beverage thick slurry, 0.1-0.19% of calcium aspartate, 0.02-0.05% of casein hydrolyzed peptide, 0.02-0.05% of hydrolyzed egg yolk powder, 0.02-0.05% of casein phosphopeptide and the balance of water. The formula comprises the following components in percentage by weight: 0.006 to 0.01 percent of zinc gluconate, 0.0005 to 0.00085 percent of zinc-rich edible yeast powder, 0.0005 to 0.00085 percent of tea theanine, 0.0005 to 0.00085 percent of N-acetylneuraminic acid, 0.0018 to 0.09 percent of a traditional Chinese medicine composition, 0.005 to 0.01 percent of L-calcium lactate, 0.0005 to 0.01 percent of collagen peptide, 0.1 to 0.3 percent of xanthan gum, 0.0005 to 0.00085 percent of melissa officinalis, 0.2 to 0.98 percent of a compound flavoring agent and the balance of purified water. Through the synergistic effect of all the components, the sleep quality is effectively improved, overactivity of bone cells is inhibited, and the bone age development is delayed.

The invention provides a chemical synthesis method of a TIMP2 protein N-terminal structural domain. An amino acid sequence of an N-terminal structural domain of TIMP2 protein is divided into four segments, the four segments are synthesized by a solid-phase polypeptide synthesis method, full-length linear polypeptide is obtained through natural chemical connection, sulfur removal and sulfydryl removal and acetamino methyl removal, finally impurities in a system are removed, the full-length linear polypeptide is dropwise added into a refolding reaction system, oxidation and refolding reactions are carried out, and the TIMP2 protein is obtained. A target product is obtained. The N-TIMP2 of the N-terminal structural domain of the TIMP2 retains the inhibitory activity of the TIMP2 on the MMP14, the N-TIMP2 obtained through chemical total synthesis can introduce non-natural amino acid to any site in the sequence or perform specific modification or mutation in the synthesis process, an effective tool is provided for researching the specific action mechanism of the N-TIMP2 and the MMP14, and a foundation is further laid for research and development of the MMP14 inhibitor.

Cosmetic method for improving skin characteristics, in which the cleansed skin surface is sprayed with water containing four-atom oxygen, known in itself as activated stabilized oxygen, and then, after the skin has absorbed the spray, the surface is coated with a preparation containing at least 0.040% by weight of hydrolyzed beta-glucan, preferably 0.1% by weight, wherein the preparation also contains at least 0.04% by weight, preferably 0.1 w% acetyl tetrapeptide-40, in the form of a gel or cream, and then the pretreated skin surface is irradiated with soft laser light emitting scattered rays with a wavelength of 700-900 nm and a power density of 40-200 mW cm2 power density, where the irradiation time is at least 30 seconds, depending on the power density. The composition contains at least 0.040% by weight of hydrolyzed beta-glucan, 1-5% by weight of a moisturizing agent, 15-20% by weight of a skin conditioning agent, 1-5% by weight of a preservative, and at least 0.04% by weight of acetyl tetrapeptide-40.

Compounds and compositions comprising compounds that modulate histone acyltransferase (HAT). Methods of treating neurodegenerative disorders, conditions associated with amyloid-beta peptide deposit accumulation, Tau protein levels, and / or alpha-synuclein accumulation, and cancer by administering to a subject a compound that modulates HAT.

The invention relates to the fields of enzyme engineering and microbial fermentation production, in particular to an N-acetylglutamate synthetase mutant for producing N-acetyl blue and application of the N-acetylglutamate synthetase mutant. According to the invention, the N-acetylglutamate synthetase mutant EcargAV323A / S435A is constructed by researching the structure of N-acetylglutamate synthetase ArgA (EcargA) from Escherichia coli and mutating the 323rd site and the 435th site of EcargA protein in combination with a directed evolution technology, so that the N-acetylglutamate synthetase mutant EcargAV323A / S435A is constructed. When the engineering strain of the N-acetylglutamate synthetase mutant is used for producing the N-acetylobservation blue through fermentation, the yield of the N-acetylobservation blue can be remarkably improved, the generation of a by-product observation blue is reduced, the fermentation process is simplified, and the production cost is reduced. The N-acetylglutamate synthetase mutant and the engineering strain provided by the invention have good industrial application value.

The invention discloses a liver-protecting beverage containing a composite plant exosome with optimized antioxidant capacity. The liver-protecting beverage comprises a plant exosome solution and a liver-protecting component, the plant exosome solution is a silybum marianum exosome solution and at least two of a Pingyin red rose exosome solution, a radix puerariae exosome solution, a turmeric exosome solution and a dandelion exosome solution; the liver protection component is at least one of silybum marianum micro-capsule powder, a radix puerariae extract, corn peptide, a dandelion extract and S-acetyl-L-glutathione. Hydroxyl and amido on small molecules are combined with lipid structures on the surfaces of multiple plant exosomes, small molecule active ingredients are combined through adsorption or reaction on the surfaces of the lipid structures of the exosomes, the oxidation resistance of the product can be improved, absorption of intestinal cells and probiotics is facilitated, cell metabolism is promoted, and then the fatigue feeling is reduced.

Described is a recombinant organism or microorganism which is capable of enzymatically converting acetyl-CoA into isobutene, (A) wherein in said organism or microorganism: (i) acetyl-CoA is enzymatically converted into acetoacetyl-CoA, (ii) acetoacetyl-CoA is enzymatically converted into 3-hydroxy-3-methylglutaryl-CoA, (iii) 3-hydroxy-3-methylglutaryl-CoA is enzymatically converted into 3-methylglutaconyl-CoA, (iv) 3-methylglutaconyl-CoA is enzymatically converted into 3-methylcrotonyl-CoA, and (v) wherein said 3-methylcrotonyl-CoA is converted into isobutene by: (a) enzymatically converting 3-methylcrotonyl-CoA into 3-methylcrotonic acid which is then further enzymatically converted into said isobutene; or (b) enzymatically converting 3-methylcrotonyl-CoA into 3-hydroxy-3-methylbutyryl-CoA which is then further enzymatically converted into 3-hydroxy-3-methylbutyric acid which is then further enzymatically converted into 3-phosphonoxy-3-methylbutyric acid which is then further enzymatically converted into said isobutene; (B) wherein said recombinant organism or microorganism has an increased pool of coenzyme A (CoA) over the organism or microorganism from which it is derived due to: (i) an increased uptake of pantothenate; and / or (ii) an increased conversion of pantothenate into CoA. Moreover, described is the use of such a recombinant organism or microorganism for the production of isobutene. Further, described is a method for the production of isobutene by culturing such a recombinant organism or microorganism in a suitable culture medium under suitable conditions.

The invention provides a blood marker for distinguishing lung cancer and non-lung cancer diseases and application of the blood marker, and belongs to the technical field of biomarkers. The blood marker for distinguishing lung cancer and non-lung cancer diseases comprises at least five metabolites as follows: phosphatidylethanolamine (36: 4), lysophosphatidylcholine 18: 1e, phosphatidylethanolamine 38: 7e, sphingomyelin d38: 5, dodecanedioic acid, N-acetylputrescine, L-glutamyl-L-glutamine, hippuric acid, trans-cyclohexane-1, 3, 4-triazole-1, 3, 4-triazole-1, 3, 4-triazole-1, 3, 4-triazole-1, 3, 4-triazole-1, 3, 4-triazole-1, 3-triazole-1, 3, 4- The compound is prepared from 1, 2-dicarboxylic acid, glycochenodeoxycholic acid, allantoic acid, L-valine, methyleucine and 4-guanidinobutyric acid. A diagnosis model is constructed based on the blood marker, and the area under curve (AUC) is greater than 0.77, which indicates that the diagnosis result is accurate and reliable. The invention provides an effective marker for diagnosis of lung cancer and differential diagnosis of lung cancer and non-lung cancer diseases, greatly simplifies experimental operation, and has important clinical diagnosis significance.

The present disclosure provides a combination comprising an antibody that specifically binds to C5 and a C5 iRNA, which is a glycoconjugate containing a ligand with a terminal N-acetylgalactosamine (GalNAc) residue and / or N-acetylglucosamine (GlcNAc) residue. A method for reducing degradation of glycoconjugate RNA by the beta-hexosaminidase enzyme is also provided. The present disclosure also includes a method for treating or preventing a C5-related disease or disorder by administering one or more doses of an anti-C5 antibody or antigen-binding fragment thereof in combination with one or more doses of a C5 iRNA; preferably, the anti-C5 antibody or fragment and the C5 iRNA are in a combination. The present disclosure also includes a dosing regimen for treating a C5-related disease or disorder with a combination of an anti-C5 antibody and a C5 iRNA in either a treatment-naive subject or a subject switching from a previous C5 inhibitor therapy.